Who cares about looking at the cornea for a contact lens eval?!

What’s new in the pipeline?

I’ve got a few things to tell you!

  • The FDA accepted Santen’s new drug application for topical cyclosporine to treat vernal keratoconjunctivitis. The company is hoping to get approval by June 2021. (via)
  • Allergan announced positive results from its phase 3 trial for its presbyopia treatment drop. Patients using the drop gained 3 lines or more in mesopic lighting versus the control. (via)
  • iVeena announced positive trial results from its keratoconus treatment drop, which upregulates lysyl oxidase and induces corneal crosslinking pharmacologically. (via)

WHAT YOUR PATIENT MIGHT ASK YOU

Are there any new dry eye treatments?

Actually, yes! The FDA just approved Eysuvis.

What is Eysuvis?

It’s loteprednol etabonate ophthalmic suspension 0.25% and was approved for the short-term treatment of the signs and symptoms of dry eye disease.

How many variations of loteprednol are there now?

Eysuvis makes five. Here’s a complete list:

1. Alrex (loteprednol etabonate ophthalmic suspension 0.2%)

2. Lotemax SM (loteprednol etabonate ophthalmic gel 0.38%)

3. Lotemax (loteprednol etabonate ophthalmic suspension 0.5%)

4. Inveltys (loteprednol etabonate ophthalmic suspension 1%)

5. Eysuvis (loteprednol etabonate ophthalmic suspension 0.25%)

Tell me more about Eysuvis.

It’s the first FDA-approved ocular corticosteroid for the treatment of dry eye disease. The drop is dosed four times daily for up to 2 weeks and uses the company’s proprietary mucus-penetrating particle drug delivery technology (Ampplify) to enhance bioavailability of the active ingredient at the target site.

Tell me about the studies.

Kala Pharmaceuticals conducted four trials (one phase 2 and three phase 3) with almost 2,900 patients involved in total. Eysuvis demonstrated significant improvements in both the signs and symptoms of dry eye disease as measured by Ocular Discomfort Severity Score and conjunctival hyperemia.

Any adverse events?

The most common was instillation site pain (5.2% patients). IOP increase was comparable to that observed with the vehicle.

When can we prescribe this?

Kala Pharmaceuticals is planning to launch Eysuvis in the United States by the end of the year. (via)


SOCIAL MEDIA ROUNDUP

Who cares about looking at the cornea for a contact lens eval?! Introducing QuickRenew.

CVS Pharmacy announced the launch of QuickRenew, an online contact lens prescription renewal tool available on the CVS Optical website. Customers can use this tool to renew their prescription with an independent ophthalmologist and order contact lenses to be shipped to their home. (via)

Need more CE?

I’ve got 11 free hours for you here! World-renowned OD and MD speakers will lecture on glaucoma, retina, dry eye, contact lens, and other topics November 20-22.


Source:

Modern Optometry

By Marion Evans